Parkinson's Disease Tulip


advertisement
Reply
 
Thread Tools Display Modes
Old 07-20-2007, 02:48 AM #1
Ronhutton's Avatar
Ronhutton Ronhutton is offline
In Remembrance
 
Join Date: Aug 2006
Location: Village of Selling, in County of Kent, UK.
Posts: 693
15 yr Member
Ronhutton Ronhutton is offline
In Remembrance
Ronhutton's Avatar
 
Join Date: Aug 2006
Location: Village of Selling, in County of Kent, UK.
Posts: 693
15 yr Member
Default BBB and Statins

I previously posted the link between the Blood-brain barrier (BBB) permeability and PD. Everything that increases permeability increases PD symptoms, everything that decreases permeability improves symptoms. In other words, we parkies have a defective BBB, with higher porosity than normal.
I mentioned that statins reduce the permeabilty of the BBB, see
http://www.ncbi.nlm.nih.gov/sites/en..._uids=16729291
and predicted statins should improve PD symptoms.
Now, evidence has been recently published showing Simvastastin reduces the incidence of PD.
http://www.eurekalert.org/pub_releas...-rfs071707.php

"Boston, MA -- Researchers from Boston University School of Medicine (BUSM) have found that the statin, simvastatin, reduces the incidence of Alzheimer’s disease and Parkinson’s disease by almost 50 percent. This is the first study to suggest that statins might reduce the incidence of Parkinson’s disease. These findings, will be published in the July online open access journal BioMed Central (BMC) Medicine."
See also,
http://www.medpagetoday.com/Neurolog...isease/tb/6202


I have found a professor who specialises in the BBB, who is interested in the connection with PD, and intends to work on it when she finishes travelling in August.

One other point on the BBB. We know stress has a catestrophic effect on PDers, and opens the pores of the BBB. Could it be that when stress widens the perneability, that carbidopa is able to enter the brain, and prevent the decarboxylation of levodopa to dopamine, causing a freeze.
Carbidopa is added to levodpa in Sinemet, to prevent breakdown of the levodopa whilst it is in the body. Carbidopa cannot normally pass the BBB.
Ron
Ronhutton is offline   Reply With QuoteReply With Quote

advertisement
Old 07-20-2007, 06:19 AM #2
Slumpy Slumpy is offline
Junior Member
 
Join Date: Feb 2007
Posts: 12
15 yr Member
Slumpy Slumpy is offline
Junior Member
 
Join Date: Feb 2007
Posts: 12
15 yr Member
Default Statins

Seems like another contradictory study to what we were all reading just a few months ago. Who knows what to believe. I stopped taking a statin as a result of reading this article below. Now maybe I should start taking it again???

---------------------------

Low cholesterol levels linked with higher risk of Parkinson's disease
• Fears that statins could cause increase in illness
• Health charities urge caution over findings

Polly Curtis, health correspondent
Monday January 15, 2007
The Guardian, United Kingdom
http://www.guardian.co.uk/frontpage/...990648,00.html

Scientists are to investigate why people with low cholesterol levels appear to be more likely to develop Parkinson's disease, following concerns that statins - given to control cholesterol - could cause an increase in the numbers of people with the illness.

About 2.3 million adults in the UK take statins to help control their cholesterol levels; the American scientists have found that those with lower levels of cholesterol are more likely to develop the degenerative neurological disorder of Parkinson's disease.

The link between statins and Parkinson's is not yet understood, and health charities last night urged caution. But the scientists behind the research warn that if they get confirmation of the finding, in their follow-up study of 16,000 people, there could be a surge in Parkinson's diagnoses in the next five years as the effects of the drug set in.

The initial study compared 124 people diagnosed with Parkinson's with a control group of 112. They found that the people with low levels of "bad" LDL cholesterol were in excess of three times more likely to be in the Parkinson's group than those with high cholesterol.

But they also found that those in the trial who took statins were less likely to develop Parkinson's disease, though the study's leader suggested this could be because the group with Parkinson's had had low cholesterol all their lives and that the effect of low cholesterol could be cumulative.

Statins are the world's biggest selling drug. The drug company Pfizer reported sales of $12.2bn (£6.2bn) for its statin, Lipitor, in 2005. The National Institute for Clinical Excellence last year recommended more people take them in the UK, raising the number of customers from 2.3 million to 5.2 million.

The head of the study, Xuemei Huang, at the University of North Carolina, said: "I'm definitely concerned [about the initial findings] which is why I'm conducting a prospective study of 16,000 people."

People should not stop taking statins, she said. The risk of heart disease in those who should be taking statins far outweighed the risk of developing Parkinson's.

The study, which is reported today in the journal Chemistry and Industry, has raised more questions than it has answered. It has not, for example, established whether low cholesterol is a cause or consequence of Parkinson's.

David Dexter, senior lecturer in neuropharmacology at Imperial College London, said: "Although the association is worrying, the study was carried out only in a small number of subjects and hence needs confirming in a larger population. Lower LDL-C levels may also be a consequence of Parkinson's and not a cause. Indeed, the study did not take into account the dietary intake of the two groups in the study, [which] may be important since some Parkinson's patients find it difficult to eat or even swallow food, thus reducing the intake of fats."

Dr Huang said the well-established link between Parkinson's and apoE2, a gene associated with lower LDL cholesterol, supported her theory that low LDL was the culprit in many cases of Parkinson's.

Kieran Breen, director of research at the Parkinson's Disease Society, said people should be wary of such a small study. "Further research into any link between low LDL cholesterol and cholesterol-lowering drugs with Parkinson's is needed. We hope that the proposed study will shed further light on this. The exact causes of Parkinson's are unknown. Research is ongoing. It is generally understood that Parkinson's [arises] from genetic and environmental factors."

Peter Weissberg, medical director of the British Heart Foundation, said: "We are concerned that any suggestion of a link between statins and Parkinson's disease would unnecessarily scare the millions of people benefiting from statins in the UK. There is no evidence to suggest that statins cause [the] disease. On the other hand, there is overwhelming evidence that statins save lives by preventing heart attacks and strokes."
blueline2.gif


'Link' Between Statins and Parkinson's Probed

Posted on: Monday, 15 January 2007, 12:00 CST
http://www.redorbit.com/news/health/...ource=r_health

EXPERTS sought to reassure patients after scientists announced they were planning an in-depth study on the link between statins and Parkinson's disease. The cholesterol-lowering drugs are taken by an estimated three million Britons and are renowned for preventing heart attacks and strokes. But now scientists are planning a detailed study after research showed a link to Parkinson's disease, which affects about 120,000 people in the UK. Charities urged people to continue taking their statins, saying the drugs saved lives. According to a report in the magazine Chemistry & Industry, researchers in the United States are planning a largescale clinical trial on the link. It comes after experts, led by Xuemei Huang from the University of North Carolina, said they had found the strongest link yet between low-density lipoprotein (LDL) cholesterol levels and Parkinson's. High levels of LDL cholesterol are linked to heart disease. Statins are known to reduce these LDL levels. The study of 124 patients revealed that those with low levels of LDL cholesterol were about three times as likely to develop Parkinson's disease as those with higher levels. Study leader Dr Xuemei Huang told the magazine she was worried by the results. "Yes I am very concerned, which is why I am planning a 16,000-patient prospective study to examine the possible role of statins, " she said.She said there could be big surges in the number of Parkinson's cases in the next five years if a link is confirmed.British experts sought to calm fears, saying there was little or no evidence of a link.Dr David Dexter, senior lecturer in neuropharmacology at Imperial College, London, said: "With the evidence we have at the moment, I would say there is not much cause for concern that statin use may cause Parkinson's disease. "The study by Huang and colleagues indicating an association between lower LDL levels and Parkinson's disease goes against current scientific beliefs."
Slumpy is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 07:59 AM #3
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default statins and BBB

One of the primary problems with the use of statins is that they possess "pleiotrophic" effects--too many biological functions depend upon, or are related to, cholesterol and /or the mavelonate pathway that is blocked by statins (HMG-CoA reductase inhibitors). On the positive side, statins are very powerful anti-inflammatory agents and are able to wonderously increase perfusion everywhere . Their short term use immediately post heart attack seems to be of unquestionable use. but to take this medication for life?

At present, research is underway determining if statins could be utilized for immunosuppression due to the effect upon T-cell suppression. and also as a cancer chemotherapeutic agent, due to statins' effects upon the small GTPases (Rho, Ras, Rab)-- statins interfere with prenylation of these translational proteins. I will make the glib observation that if you are planning on a transplant or developing cancer, possibly statins are a good bet (though the original Pravachol trial "CARE" found a 1200% relative increase in breast cancer in the women in their trial--this statistic was deemed "an anomoly" due to the fact that the placebo group only had 1 incident, a # less than expected, though increases in cancer have been found in statin treatment groups from many other studies, esp. in elderly (>70 yrs) males.

Cholesterol has recently been found to be ESSENTIAL to the neuronal synapses in the brain and
ApoE is the most abundant apolipolipid in the brain and delivers cholesterol to the neurons. (studies with statins and alzheimer's utilizing statins to decrease ApoE4 are Still underway. Problem with these studies is that initially one would expect some benefit from statins due to their anti inflammatory effects, but IF they ran long enough (ie >5 ys) any effects w/ depletion of cholesterol would be evident. Cholesterol is made de novo in the brain itself; cholesterol cannot cross the blood brain barrier, so the brain has its own mavelonate pathway to its production. and fortunately, brain cholesterol has a VERY LONG HALF LIFE--5 yrs. any studies that last <5yrs (almost ALL pharmaceutical studies) will not pick up the effects of lowered brain cholesterol and ApoE. Recently, Alzheimer's reserach has been shifting toward increases in tau phosphorylation as etiopathogenic in Alzheimer's--and statins increase tau phosphorylation. statins are studied in alzheimer's because they specifically decrease ApoE--the substance responsible for transporting cholesterol to the neurons for synaptic functions to occur. with the newest information that Apoe is essential for neuronal synapses, manipulating cholesterol and apoe for alzheimer's seems more than a questionable undertaking.

NEUROBIOLOGY:
Cholesterol--Making or Breaking the Synapse
Ben A. Barres and Stephen J. Smith
Synapses are regions where neurons meet and communicate. But how is their formation regulated in the developing and adult brain? As Smith and Barres explain in their Perspective, the answer could not be simpler. It turns out that, at least in the culture dish, a type of glial cell called an astrocyte produces the molecule cholesterol, which is taken up by neurons and then directs formation of synapses perhaps by regulating vital signaling pathways (Mauch et al.).

Neurons need cholesterol secreted by glial cells to form and maintain functional synapses. And cholesterol is necessary for synaptogenesis and probably for production and transport of vesicles necessary for neurotransmission. If one accepts the concept of neuronal plasticity in the adult brain, then deliberately suppressing cholesterol metabolism in the brain seems questionable.

(to be continued in next post)
madelyn
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 09:30 AM #4
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default additional article --in vitro effects of statins

Journal of Neurochemistry
Volume 89 Page 24 - April 2004
doi:10.1046/j.1471-4159.2003.02305.x
Volume 89 Issue 1


HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis
Joachim G. Schulz, Julian Bösel, Magali Stoeckel, Dirk Megow, Ulrich Dirnagl and Matthias Endres
Abstract

To determine whether neurite outgrowth depends upon the mevalonate pathway, we blocked mevalonate synthesis in nerve growth factor-treated PC12 cells or primary cortical neurones with atorvastatin, a 3-hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and substituted different intermediates of the mevalonate pathway. We show that HMG-CoA reductase inhibition causes a profound reduction of neurite length, neurite loss and ultimatively cell death in undifferentiated and pre-differentiated PC12 cells and also in rat primary cortical neurones. Geranylgeranylpyrophosphate, but not farnesylpyrophosphate, squalene or cholesterol, completely compensated for the lack of mevalonate. Our data indicate that, under HMG-CoA reductase inhibition, geranylgeranylpyrophosphate rather than farnesylpyrophosphate or cholesterol is critical for neurite outgrowth and/or maintenance. Loss of neurites is an early manifestation of various neurodegenerative disorders, and dysfunction of isoprenylation might play a role in their pathogenesis.

#2:
Neurodegenerative Disorders and Cholesterol
Author: Makoto Michikawa1

Source: Current Alzheimer Research, Volume 1, Number 4, November 2004, pp. 271-275(5)

Abstract:

It has been suggested that a high serum cholesterol level is a risk factor for Alzheimer's disease (AD), that treatment with cholesterol-lowering drugs (statins) reduces the frequency of AD development, and that the polymorpholism of genes encoding proteins regulating cholesterol metabolism is associated with the frequency of AD development. However, the mechanism by which high serum cholesterol level leads to AD, still remains unclarified. Several recent studies have shown the results challenging the above notions. Here another notion is proposed, that is, a low high-density lipoprotein (HDL) level in serum and cerebro-spinal fluid (CSF) is a risk factor for the development of AD; moreover, the possibility that AD and Niemann-Pick type C disease share a common cascade, by which altered cholesterol metabolism leads to neurodegeneration (tauopathy) is discussed. In this review, the association between cholesterol and AD pathogenesis is discussed from different viewpoints and several basic issues are delineated and addressed to fully understand the mechanisms underlying this relationship.
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 09:42 AM #5
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default case presesntation of patient with statin induced PD

Do statins induce Parkinsons?
The following study and letter in response was
published in the German
medical journal Der Nervenarzt.
~~~~~~~~~~~~~~~~~~~~
Study on statin myopathy:

Der Nervenarzt
Publisher: Springer-Verlag Heidelberg
ISSN: 0028-2804 (Paper) 1433-0407 (Online)
DOI: 10.1007/s00115-002-1445-6
Issue: Volume 74, Number 2
Date: February 2003
Pages: 115 - 122
Fibrat-/Statin-Myopathie


~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Letter in response with case study of
statin-unmasked Parkinsons

"To the excellent review about the development
of myopathies following long-term medication of
cholesterol level decreasing fibrates and statins, there
should be considered additional differential diagnostic
possibilities.

Because of the similar clinical symptomatology
with muscle aches and increased stiffness, the
diagnosis of statin-> induced aggravated
Parkinson Disease Syndrome should be
discussed. The development of such muscular
side effects is seen more with statins than with
fibrates.

The case report in Table 1 indicates the
history of a 60 year old patient with statin-induced
Parkinson Syndrome occurring over a long time.

On the other hand, with central effective
statins, a possible neuro-protective effect in
neuro-degenerative diseases has been considered,
especially in dementia. But long term use of statins,
especially Lovastatin, leads to the reduction of
coenzyme Q10 and can cause damage of the
mitochondrial breathing chain. Co Q-10 is an electron
receptor in the mitochondrial complexes 1 and 2 and
very effective absorber of radicals. This antigen
substance increases the complex 1 activity.
Co-Q10 shows a certain therapeutic effect with
encephalomyopathy where there is a lack of
various enzyme functions of the breathing chain.

Dysfunction of various parts of the mitochondrial
breathing chain is also considered in the
pathophysiological mechaism of idiopathic
Parkinson's disease.

Treatment with Co-Q10 in patients who are not
treated with Dopamine for Parkinson patients,
caused less disease symptomatology and
progression than patients treated with
placebo, though placebo treatment can cause
stimulation of dopaminergic neurotransmission.
Therefore, the long-term treatment with Co-Q10
possibly is neuroprotective in idiopathic morbid
Parkinson, though new evidence shows it
appears to cause mild symptomatic effect.

Under these circumstances treatment with
prophylactic medication of Co-Q10 which has
been well tolerated in doses up to 1200mgm in
patients with neurodegenerative diseases should
be considered for statin myopathy or statin-
induced Parkinson syndrome in addition to
discontinuation of the cholesterol decreasing
medication.

The Table 1 summarizes a patient with Parkinson
syndrome.

1995: start of therapy with Fluvastatin 40 mg.

1997: increasing weakness with shoulder and hip
pain on the right

1999: diagnosis of right sided Parkinson
syndrome of akinetic dominance type.
Careful induction of Pergolid with daily doses
of 3 mg and Salagen 7.5 mgm

2000: complaints about increasing edema
development in legs, loss of hair, start of a
potas.sium sparing diuretic and increasing
of Pergolid medication from 4.5 mg
in June 2000 to 6 mgm in December.

March 2001: discontinuation of Fluvastatin,
continuation of Pergolid 6 mg

June 2001: reduction of Pergolid to 4 mgm

Sept 2001 Pergolid 3 mgm. Improvement of edema

December 2001 discontinuation of Pergolid and
diuretics

March, 2002 discontinuation of Salagen"

Dr. Th. T. Muller
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 10:26 AM #6
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default

onto another "pleiotrophic effect: of statins--lowering coenzyme Q10. Of the 15 studies published concerning coq10 levels and statin use in humans, 9 have unequivocally shown decreases in either muscle coq10, platelet CoQ10, or plasma coq10. In 1990, Merck received 2 patents for manufacturing a preparation containing a statin and coenzyme Q10:

Patent Number: 4,933,165 Patent Number: 4,929,437

Below is a verbatim sample from Patent Number 4,933,165.

"What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutical carrier and an effective antihypercholesterolemic amount of an HMG-CoA reductase inhibitor and an amount of Coenzyme Q.sub.10 effective to counteract HMG-CoA reductase inhibitor-associated skeletal muscle myopathy.

2. A composition of claim 1 in which the HMG-CoA reductase inhibitor is selected from: lovastatin, simvastatin, pravastatin and sodium-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(methylethyl)-1H-Indole-2yl]- hept-6-enoate.

3. A method of counteracting HMG-CoA reductase inhibitor-associated skeletal muscle myopathy in a subject in need of such treatment which comprises the adjunct administration of a therapeutically effective amount of an HMG-CoA reductase inhibitor and an effective amount of Coenzyme Q.sub.10 to counteract said myopathy.

4. A method of claim 3 in which the HMG-CoA reductase inhibitor is selected from the group consisting of: lovastatin, simvastatin, pravastatin and sodium-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(methylethyl)-1H-Indole-2yl]- hept-6-enoate."

The company answer as to why the preparation was never manufactured, but patented, was that they wanted the exclusive patent in case somewhere in the future it was shown that depleting coq10 was not desirable and needed therapy.....(complicating the manufacturing of these combined suibstances is the fact that coenzyme q10 is manufactured almost exclusively by 4 companies in Japan these companies hold the patents on the manufacturing processes--interestingly enough one of these processes is based upon Tobacco leaves fermentation!)--they cannot make enough of the substance to be included in every statin taken by the millions of people who are on them.)

Ghirlanda G, et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA
reductase inhibitors, J of Clin Pharm 1993;33(3):226-229.

The abstract concludes:“Our data show that the treatment with HMG-CoA
reductase inhibitors lowers both total cholesterol and CoQ10 plasma levels
in normal volunteers and in hypercholesterolemic patients. CoQ10 is
essential for the production of energy and also has antioxidative
properties. A diminution of CoQ10 availability may be the cause of membrane
alteration with consequent cellular damage."

CoEnzyme Q10 is a major component of the mitochondrial electron
transport system, intricately involved in the production of ATP. Loss of
this function of Coenzyme Q10 results in dramatic energy depletion for all
cells. Coenzyme Q10 also functions as a major antioxidant in the central
nervous system,“neutralizing" reactive oxygen species produced during ATP
production. Reactive oxygen species that are not neutralized may cause cell
death, the definition of oxidative stress.
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson

Last edited by olsen; 07-20-2007 at 10:56 AM.
olsen is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 11:46 AM #7
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default coq10 and statins

I am repeating several earlier posts, but recall the original article authored by clifford Shults, et al published in annals of neurology, 2002, showing a decrease in progression of disease in early onset PD patients who received 1200 mgm/day of coenzyme Q10. this was a small study (80 patients total),thus multiple center studies are underway using megadose coq10 in PD, ALS and huntington's. (recent published data from these studies concluded that use of megadose coq10 was "safe and tolerable".)

there are published studies in humans looking at statins and coq10 levels--in many of these studies, incontrovertible evidence that statins use lowers muscle, platelet or serum coq10 is available. 3 other studies were "inconclusive". CoQ10 is an essential element of the mitochondrial process that makes cellular energy--ATP. It also functions as one of the major anti-oxidants within the mitochondria, helping decrease reactive oxygen species. (important information, relating to the theory that PD is caused in part by mitochondrial dysfunction)
Again a repeat: Dr. Lieberman did a small study looking at progression rates of 2 different groups of PD patients--one taking a statin, the other not on statins., His conclusion after following these 2 groups after a period of (i think ~2yrs) was that their rates of progression were "similar". Included in this study was a small paragraph noting that of the original group who were not taking a statin, 5 patients were started on a statin during the trial period. Importantly (to me anyway) was the fact that ALL FIVE PATIENTS EXPERIENCED AN INCREASE IN SEVERITY OF THEIR SYMPTOMS AFTER STARTING A STATIN. I know that is a small #, but that's 100% of all the patients who were started on a statin during the trial period. the statin was stopped for a "washing out" period and when the symptoms did not revert, the drug was re-started. Does not increasing severity of symptoms qualify as "progression of disease?
There are NO scientific studies determining time for "wash out" of statins. Dr. Paul Phillips, interventional cardiologist from san diego who has been studying statin maintains that the plasma half life of statins is known, but the muscle tissue half life is not known, and may be the more important # in determining half life of statins.
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 12:13 PM #8
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default Pleiotrophic effects of statins and some consequences

Excerpted from an article available online:
Steven K Baker MD and Mark A. Tarnoplasky, MD PhD. Statin myopathies: phathophysiologic and clinical perspectives. Clin Invest Med 2001; 24(5): 258-72

Cholesterol biosynthesis and the isoprenoids:
The inhibition of HMG-CoA reductase by the HMGRIs
is approximately 14 steps and 9 to 10 enzymatic
reactions removed from the terminal step(s) in cholesterologenesis
Furthermore,
mevalonic acid, the immediate product of HMG-CoA
reductase, is a pivotal precursor intermediate which
gives rise to the vital isoprenoids en route to cholesterol.
It is not surprising, therefore, that inhibiting this
important biosynthetic pathway causes pleiotropic
metabolic consequences33,34 (Fig. 1).
Prenylation is a fundamental element of posttranscriptional
lipid modification of proteins and other
compounds and affects their function. Some of the
known isoprenoids include the following: (1)
isopentyladenosine, required for transfer RNA synthesis;
(2) dolichols, required for glycoprotein synthesis;
(3) heme A, a polyisoprenoid component of the electron
transport chain; and (4) ubiquinone, a polyisoprenylated
quinoid cofactor of the electron transport
chain, which accepts electrons from complexes I and
II.6,35,… It is estimated that
over 1% of mammalian cellular proteins are isoprenylated.
38 Isoprenylated proteins have been implicated in
smooth muscle cell migration and proliferation,33 and
skeletal muscle cell growth and differentiation.39–42
These conclusions were borne out of experiments in
which statin treatment impaired cell development in
culture, whereas the coapplication of mevalonate or
its distal metabolites (i.e., farnesol or geranylgeraniol)
reversed many of the inhibitory cellular effects of
statins.

in reference to #1--interference with tRNA--statins interfere with selenoprotein tRNA, and specifically decrease selenoprotein N. the glutathione peroxidase family, and the thioredoxin reductases, were recently identified as selenoproteins. theoretically, thru this action, statins could interfere with glutathione reductase activity which re-cycles glutathione within the brain--the major anti-oxidant within the brain.

in reference to #2--dolichols--the substantia nigra is composed largely of lipids. the Most abundant lipid comprising the Substantia Nigra is DOLICHOLS- accounting for up to 45% of the total amt of lipids within this structure.

# 3--decreasing heme A--recent evidence that reduced heme A is a pathologic finding in alzheimer's

statins also interfere with the funciton of lipid rafts --important functions of lipid rafts in refererence ot neuro system:

excerpted from "Membrane Lipid Rafts and their role in Axon Guidance. Guirland, C and Zheng, J Q.


"...Lipid rafts have recently received considerable attention because they are thought to be involved in many cellular functions, in particular, signal transduction for extracellular stimuli. Many of these functions
are also intimately related to the processes involved in neural development, including neurotrophic factor signaling and synaptic plasticity. Recent studies from our lab and others have indicated an important role for lipid rafts in axonal growth and guidance. Specifically, our data show that lipid rafts on the plasma membrane provide platforms for spatial and temporal
control of guidance signaling by extracellular cues..."
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 12:41 PM #9
olsen's Avatar
olsen olsen is offline
Senior Member
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
olsen olsen is offline
Senior Member
olsen's Avatar
 
Join Date: Aug 2006
Posts: 1,860
15 yr Member
Default statins

Okay, even I am getting on my nerves with all this now-- and I research this stuff most days. forgive my perseverance.

I am aware with posting on this controversial subject i will provoke many who are taking statins or feel they may be worthwhile in treating PD....If you feel conflicted, discuss it with your physician. I do not have answers--just lots and lots of unanswered questions combined with lots and lots of research that makes me suspicious of statin use and neuro diseases..
I will end by stating that I do not have the qualifications to tell anyone what to do in terms of treatment with statins. The evidence that statins are beneficial for middle aged men who have suffered a cardiovascular event is not in question---(I feel they should be used in acute situations, briefly)the use for any one else, I feel is in question. there has NEVER been evidence showing statins decrease mortality in women or men >65. the use of statins for primary prevention (ie for individuals with minor cardiac risk, has not been shown to decrease mortality--as a matter of fact in a study of older men, the mortality in the treated group was higher than in the placebo group.....)

I am sharing the (obviously selected) information about statins and their relationship to the neurological system. I am convinced statins played a major role in my husband's development of PD, as I am almost convinced it did in my niece's husband's development of PD with lewy body disease and my dear friend's husband's development of PD. If these are instances of a genetic predisposition interacting with an environmental stimulus (in this case a statin) to produce parkinson's, given the millions of people taking statins., the numbers affected with a neurological diseasse could be enormous.
there have been several case reports of neuromuscular disorders being "unmasked" by statin use (and the internet is filled with self reported instances of ALS related statin cases).

there exists a web site, founded and maintained by a physician who suffered 2 episodes of transient global amnesia he attributes to statins. He presents his research findings and a forum for members to discuss their symptoms, etc. He was trained as an astronaut, thus his web address:\


http://www.spacedoc.net.

madelyn
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices.

~ Jean-Martin Charcot


The future is already here — it's just not very evenly distributed. William Gibson
olsen is offline   Reply With QuoteReply With Quote
Old 07-20-2007, 05:07 PM #10
Ronhutton's Avatar
Ronhutton Ronhutton is offline
In Remembrance
 
Join Date: Aug 2006
Location: Village of Selling, in County of Kent, UK.
Posts: 693
15 yr Member
Ronhutton Ronhutton is offline
In Remembrance
Ronhutton's Avatar
 
Join Date: Aug 2006
Location: Village of Selling, in County of Kent, UK.
Posts: 693
15 yr Member
Default Statins

Madelyn,
Many thanks for your input, putting the alternative, or contradictory evidence on the effects of taking statins.
Like you, I am not recommending what people should take. I am just trying to assemble all the evidence I can find relating to the BBB. Maybe the conflict of whether statins improve or exacerbate the symptons of PD depends on which statin you use. The researchers from Boston University found Simvastatin gave the best improvement in PD. Do you know which statins the 3 people you mention who had adverse effects? Possibly atorvastatin or lovastatin? I have not yet been able to find what effect these other statins have on the BBB.
Thanks again for the terrific amount of work you have posted on the topic.
Best wishes
Ron
Ronhutton is offline   Reply With QuoteReply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off


Similar Threads
Thread Thread Starter Forum Replies Last Post
Statins again and please no Alkymst Peripheral Neuropathy 14 09-02-2015 01:11 PM
Statins may increase risk of ALS pantos Multiple Sclerosis 1 07-11-2007 03:24 PM
Anyone here on statins??? Yorkiemom Peripheral Neuropathy 25 06-17-2007 08:11 PM
Statins and ALS-like syndrome olsen ALS 4 06-11-2007 12:26 AM


All times are GMT -5. The time now is 09:18 AM.

Powered by vBulletin • Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.

vBulletin Optimisation provided by vB Optimise v2.7.1 (Lite) - vBulletin Mods & Addons Copyright © 2024 DragonByte Technologies Ltd.
 

NeuroTalk Forums

Helping support those with neurological and related conditions.

 

The material on this site is for informational purposes only,
and is not a substitute for medical advice, diagnosis or treatment
provided by a qualified health care provider.


Always consult your doctor before trying anything you read here.